Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets

Neuroscience

Volumn 115, Issue 4, 2002, Pages 1047-1058

  Tel, B C ^a   Zeng, B Y ^a   Cannizzaro, C ^a   Pearce, R K B ^a   Rose, S ^a   Jenner, P ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Dopamine agonists; Dyskinesia; L DOPA; Peptide mRNAs; Primates

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ADENOSINE A2 RECEPTOR; BROMOCRIPTINE; LEVODOPA; MAZINDOL; MESSENGER RNA; NEUROPEPTIDE; PREPROENKEPHALIN; PREPROTACHYKININ; PRODYNORPHIN; ROPINIROLE; TRITIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CAUDATE NUCLEUS; CELL LOSS; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DYSKINESIA; FEMALE; IN SITU HYBRIDIZATION; INVOLUNTARY MOVEMENT; LOCOMOTION; MALE; MARMOSET; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUTAMEN; STRIATE CORTEX;

ANIMALS; ANTIPARKINSON AGENTS; BROMOCRIPTINE; CALLITHRIX; DOPAMINE UPTAKE INHIBITORS; DYSKINESIA, DRUG-INDUCED; ENKEPHALINS; FEMALE; INDOLES; LEVODOPA; MALE; MAZINDOL; NEOSTRIATUM; NEURAL PATHWAYS; NEUROPEPTIDES; PARKINSONIAN DISORDERS; PROTEIN PRECURSORS; RECEPTORS, PURINERGIC P1; RNA, MESSENGER; TACHYKININS;

EID: 0037121621     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(02)00535-3     Document Type: Article

References (62)

1. Ahlskog J.E., Muenter M.D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord. 16:2001;448-458.
2. Asselin M.C., Soghomonian J.J., Cote P.Y., Parent A. Striatal changes in preproenkephalin messenger-RNA levels in Parkinsonian monkeys. NeuroReport. 5:1994;2137-2140.
3. Augood S.J., Emson P.C. Adenosine A(2a) receptor messenger-RNA is expressed by enkephalin cells but not by somatostatin cells in rat striatum - A study. Mol. Brain Res. 22:1994;204-210.
4. Augood S.J., Emson P.C., Mitchell I.J., Boyce S., Clarke C.E., Crossman A.R. Cellular localization of enkephalin gene-expression in MPTP-treated Cynomolgus monkeys. Mol. Brain Res. 6:1989;85-92.
5. Barone P., Bravi D., Bermejo-Pareja F., Marconi R., Kulisevsky J., Malagu S., Weiser R., Rost N. Pergolide monotherapy in the treatment of early PD - A randomized, controlled study. Neurology. 53:1999;573-579.
6. Bedard, P., Gomez-Mancilla, B., Blanchette, P., Gagnon, C., Falardeau, P., DiPaolo, T., 1993. Role of Selective D-1 and D-2 Agonists in Inducing Dyskinesia in Drug-naive MPTP Monkeys. Raven Press, New York, pp. 113-118.
7. Bedard P.J., Dipaolo T., Falardeau P., Boucher R. Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-Parkinsonian monkeys - Correlation with [H-3] spiperone binding. Brain Res. 379:1986;294-299.
8. Blanchet P.J., Calon F., Martel J.C., Bedard P.J., Dipaolo T., Walters R.R., Piercey M.F. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D-2 agonist 91356U in MPTP-exposed monkeys. J. Pharmacol. Exp. Ther. 272:1995;854-859.
9. Bordet R., Ridray S., Carbon S., Diaz J., Sokoloff P., Schwartz J.C. Induction of dopamine D-3 receptor expression as a mechanism of behavioral sensitization to levodopa. Proc. Natl. Acad. Sci. USA. 94:1997;3363-3367.
10. Boyce S., Rupniak N.M.J., Steventon M.J., Iversen S.D. Characterization of dyskinesias induced by L-DOPA in MPTP-treated squirrel monkeys. Psychopharmacology. 102:1990;21-27.
11. Cadet J.L., Zhu S.M., Angulo J.A. Quantitative in situ hybridization evidence for differential regulation of proenkephalin and dopamine D2-receptor messenger-RNA levels in the rat striatum - Effects of unilateral intrastriatal injections of 6-hydroxydopamine. Mol. Brain Res. 12:1992;59-67.
12. Cenci M.A., Lee C.S., Bjorklund A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 10:1998;2694-2706.
13. Comb M., Seeburg P.H., Adelman J., Eiden L., Herbert E. Primary structure of the human met-enkephalin and leu-enkephalin precursor and its messenger-RNA. Nature. 295:1982;663-666.
14. Crossman A.R. A hypothesis on the pathophysiological mechanisms that underlie levodopa-induced or dopamine agonist-induced dyskinesia in Parkinsons-disease - Implications for future strategies in treatment. Mov. Disord. 5:1990;100-108.
15. DeLong M.R. Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 13:1990;281-285.
16. Di Monte D.A., McCormack A., Petzinger G., Janson A.M., Quik M., Langston W.J. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model. Mov. Disord. 15:2000;459-466.
17. Duty S., Brotchie J.M. Enhancement of the behavioral response to apomorphine following repeated treatment in the 6-hydroxydopamine-lesioned rat temporally correlated with a rise in striatal preproenkephalin-B, not preproenkephalin-A, gene expression. Exp. Neurol. 144:1997;423-432.
18. Fabbrini G., Juncos J., Mouradian M.M., Serrati C., Chase T.N. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinsons disease. Ann. Neurol. 21:1987;370-376.
19. Fabbrini G., Mouradian M.M., Juncos J.L., Schlegel J., Mohr E., Chase T.N. Motor fluctuations in Parkinsons disease - Central mechanisms. Ann. Neurol. 24:1988;366-371.
20. Ferre S., Fredholm B., Morelli M., Popoli P., Fuxe K. Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in basal ganglia. Trends Neurosci. 20:1997;482-487.
21. Fink J.S., Weaver D.R., Rivkees S.A., Peterfreund R.A., Pollack A.E., Adler R.S. Molecular cloning of the rat adenosine-A2 receptor - Selective coexpression with D2-dopamine receptors in rat striatum. Mol. Brain Res. 14:1992;186-195.
22. Flaherty A.W., Graybiel A.M. Input-output organization of the sensorimotor striatum in the squirrel monkey. J. Neurosci. 14:1994;599-610.
23. Furlong T.J., Pierce K.D., Selbie L.A., Shine J. Molecular characterization of a human brain adenosine-A2 receptor. Mol. Brain Res. 15:1992;62-66.
24. Fuxe K., Ferre S., Zoli M., Agnati L.F. Integrated events in central dopamine transmission as analyzed at multiple levels. Evidence for intramembrane adenosine A(2A) D-2 and adenosine A(1) dopamine D-1 receptor interactions in the basal ganglia. Brain Res. Rev. 26:1998;258-273.
25. Gerfen C.R., Engber T.M., Mahan L.C., Susel Z., Chase T.N., Monsma F.J., Sibley D.R. D1 and D2 dopamine receptor regulated gene expression of striatonigral and striatopallidal neurons. Science. 250:1990;1429-1432.
26. Gnanalingham K.K., Milkowski N.A., Smith L.A., Hunter A.J., Jenner P., Marsden C.D. Short-term and long-term changes in striatal and extrastriatal dopamine uptake sites in the MPTP-treated common marmoset. Eur. J. Pharmacol. 277:1995;235-241.
27. Harmar A.J., Armstrong A., Pascall J.C., Chapman K., Rosie R., Curtis A., Going J., Edwards C.R.W., Fink G. cDNA sequence of human beta-preprotachykinin, the common precursor substance-P and neurokinin-a. FEBS Lett. 208:1986;67-72.
28. Henry B., Crossman A.R., Brotchie J.M. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Exp. Neurol. 155:1999;204-220.
29. Herrero M.T., Augood S.J., Hirsch E.C., Javoyagid F., Luquin M.R., Agid Y., Obeso J.A., Emson P.C. Effects of L-DOPA on preproenkephalin and preprotachykinin gene-expression in the MPTP-treated monkey striatum. Neuroscience. 68:1995;1189-1198.
30. Holloway R., Shoulson I., Kieburtz K., McDermott M., Tariot P., Kamp C., Day D., Shinaman A., Fahn S., Lang A., Marek K., Seibyl J., Weiner W., Welsh M., Pahwa R., Coe S., Barclay L., Sutherland L., Hildebrand K., Hubble J., Weeks C., LeWitt P., Miyasaki J., Duff J., Sime E., Suchowersky O., Stacy M., Kurth M., Brewer M., Harrigan M., Russell D.S., Fussell B., Ford B., Dillon S., Hammerstad J., Stone C., Riley D., Rainey P., Standaert D., Tennis M., Wooten F., Rost-Ruffner E., Factor S., Brown D., Jankovic J., Atassi F., Kurlan R., Gardiner I., Panisset M., Amyot D., Hall J., Rajput A., Shirley T., Rodnitzky R., Dobson J., Shults C., Fontaine D., Waters C., Welsh M., Schuman S., Pfeiffer R., Rast S., Pfeiffer B., Brocht A., Casaceli C., Daigneault S., Hodgeman K., Honsinger K., O'Connell C., Watts A. Pramipexole vs levodopa as initial treatment for Parkinson's disease - A randomized controlled trial. J. Am. Med. Assoc. 284:2000;1931-1938.
31. Horikawa S., Takai T., Toyosato M., Takahashi H., Noda M., Kakidani H., Kubo T., Hirose T., Inayama S., Hayasida H., Miyata T., Numa S. Isolation and structural organisation of human preproenkephalin B gene. Nature. 306:1983;611-614.
32. Javitch J.A., Damato R.J., Strittmatter S.M., Snyder S.H. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine - Uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natl. Acad. Sci. USA. 82:1985;2173-2177.
33. Jolkkonen J., Jenner P., Marsden C.D. L-DOPA reverses altered gene-expression of substance-P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP. Mol. Brain Res. 32:1995;297-307.
34. Kanda T., Jackson M.J., Smith L.A., Pearce R.K.B., Nakamura J., Kase H., Kuwana Y., Jenner P. Adenosine A(2a) antagonist: A novel antiparkinsonian agent that not provoke dyskinesia in Parkinsonian monkeys. Ann. Neurol. 43:1998;507-513.
35. Lees A.J., Stern G.M. Sustained bromocriptine therapy in previously untreated patients Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 44:1981;1020-1023.
36. Levy R., Hazrati L.N., Herrero M.T., Vila M., Hassani O.K., Mouroux M., Ruberg M., Asensi H., Agid Y., Feger J., Obeso J.A., Parent A., Hirsch E.C. Re-evaluation of the functional anatomy of the basal ganglia in normal and parkinsonian states. Neuroscience. 76:1997;335-343.
37. Maneuf Y., Mitchell I., Crossman A., Brotchie J. On the role of enkephalin cotransmission in the GABAergic striatal efferents to the globus pallidus. Exp. Neurol. 125:1994;65-71.
38. Maratos E.C., Jenner P., Duty S. Preproenkephalin-B gene expression in the caudate-putamen of normal monkeys exhibiting L-DOPA-induced dyskinesia. Br. Neurosci. Assoc. Abstr. 16:2001;36.11.
39. Marsden, C., Parkes, J., Quinn, N., 1981. Fluctuations of Disability in Parkinson's Disease: Clinical Aspects. Butterworth, London, pp. 96-122.
40. Martinez-Mir M.I., Probst A., Palacios J.M. Adenosine-A2 receptors - Selective localization in the human basal ganglia and alterations with disease. Neuroscience. 42:1991;697-706.
41. Mayfield R.D., Larson G., Orona R.A., Zahniser N.R. Opposing actions of adenosine A(2a) and dopamine D-2 receptor activation on GABA release in the basal ganglia: Evidence for an A(2a)/D-2 receptor interaction in globus pallidus. Synapse. 22:1996;132-138.
42. Mori, A., Shindou, T., 2000. Physiology of adenosine receptors in the striatum. In: Kase, H., Richardson, P.J., Jenner, P. (Eds.), Adenosine Receptors and Parkinson's Disease. Academic Press, San Diego, CA, pp. 107-127.
43. Morissette M., Grondin R., Goulet M., Bedard P.J., Di Paolo T. Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D-1 or D-2 receptor agonists. J. Neurochem. 72:1999;682-692.
44. Nisbet A.P., Foster O.J.F., Kingsbury A., Eve D.J., Daniel S.E., Marsden C.D., Lees A.J. Preproenkephalin and preprotachykinin messenger-RNA expression in normal human basal ganglia and in Parkinson's disease. Neuroscience. 66:1995;361-376.
45. Nutt J.G. Levodopa-induced dyskinesia - Review, observations, and speculations. Neurology. 40:1990;340-345.
46. Obeso J.A., Rodriguez-Oroz M.C., Rodriguez M., DeLong M.R., Olanow C.W. Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: Problems with the current model. Ann. Neurol. 47:2000;S22-S34.
47. Olanow, C., Alberts, M., 1985. Low Dose Bromocriptine in Previously Untreated Parkinson Patients. Raven Press, New York, pp. 315-321.
48. Olanow C.W., Fahn S., Muenter M., Klawans H., Hurtig H., Stern M., Shoulson I., Kurlan R., Grimes J.D., Jankovic J., Hoehn M., Markham C.H., Duvoisin R., Reinmuth O., Leonard H.A., Ahlskog E., Feldman R., Hershey L., Yahr M.D. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to sinemet(R) in Parkinson's disease. Mov. Disord. 9:1994;40-47.
49. Olanow C.W., Obeso J.A. Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease - Implications for the early use of COMT inhibitors. Neurology. 55:2000;S72-S77.
50. Parent A., Sato F., Wu Y., Gauthier J., Levesque M., Parent M. Organization of the basal ganglia: the importance of axonal collateralization. Trends Neurosci. 23:2000;S20-S27.
51. Pearce R.K.B., Banerji T., Jenner P., Marsden C.D. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-DOPA in the MPTP-treated marmoset. Mov. Disord. 13:1998;234-241.
52. Pearce R.K.B., Heikkila M., Linden I.B., Jenner P. L-dopa induces dyskinesia in normal monkeys: Behavioural and pharmacokinetic observations. Psychopharmacology. 156:2001;402-409.
53. Pearce R.K.B., Jackson M., Smith L., Jenner P., Marsden C.D. Chronic L-DOPA administration induces dyskinesias in the phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus). Mov. Disord. 10:1995;731-740.
54. Rascol A., Montastruc J.L., Guiraudchaumeil B., Clanet M. Bromocriptine as first treatment of Parkinson's disease - Long-term results. Rev. Neurol. 138:1982;401-408.
55. Rascol O., Brooks D.J., Korczyn A.D., De Deyn P.P., Clarke C.E., Lang A.E. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. New Engl. J. Med. 342:2000;1484-1491.
56. Rinne U.K. New strategies in the treatment of early Parkinson's disease. Acta Neurol. Scand. 84:1991;95-98.
57. Schiffmann S.N., Jacobs O., Vanderhaeghen J.J. Striatal restricted adenosine-A2 receptor (Rdc8) is expressed by enkephalin but not by substance-P neurons - An in situ hybridization histochemistry study. J. Neurochem. 57:1991;1062-1067.
58. Schiffmann S.N., Libert F., Vassart G., Vanderhaeghen J.J. Distribution of adenosine-A2 receptor messenger-RNA in the human brain. Neurosci. Lett. 130:1991;177-181.
59. Stephan, H., 1980. The Brain of the Common Marmoset: A Stereotactic Atlas, Springer-Verlag, Berlin.
60. Young W.S., Bonner T.I., Brann M.R. Mesencephalic dopamine neurons regulate the expression of neuropeptide messenger-RNAs in the rat forebrain. Proc. Natl. Acad. Sci. USA. 83:1986;9827-9831.
61. Zeng B.Y., Jolkkonen J., Jenner P., Marsden C.D. Chronic L-DOPA treatment differentially regulates gene expression glutamate decarboxylase, preproenkephalin and preprotachykinin in striatum of 6-hydroxydopamine-lesioned rat. Neuroscience. 66:1995;19-28.
62. Zeng B.Y., Pearce R.K.B., MacKenzie G.M., Jenner P. Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with L-DOPA. Eur. J. Neurosci. 12:2000;1096-1104.